Clinical Trial Update: Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the antihypertensive efficacy and safety of fixed-dose candesartan/hydrochlorothiazide (32/12.5 mg and 32/25 mg) versus candesartan 32 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Candesartan (candesartan)
• Candesartan/Hydrochlorothiazide (candesartan/hydrochlorothiazide)

Snippet

Sponsor: AstraZeneca | Conditions: Hypertension | Phase 3 | Status: COMPLETED